Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for New-onset AChR-Myasthenia Gravis
NCT07071246Active, not recruiting
- Sponsor
- Tangdu Hospital
- Start
- Aug 2022
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of rituximab in myasthenia gravis (MG), sponsored by Tangdu Hospital. Primary endpoints: Proportion of patients reaching Minimal Manifestation (MM) or better status at 12 months, Proportion of patients reaching Clinical Complete Remission (CSR) at 24 months and 1 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07071246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071246.